Tebentafusp continues to provide long-term OS benefit in previously untreated patients with unresectable or metastatic uveal melanoma

Дата публикации: 21-09-2026 07:09:00

Findings from the final 5-year analysis of overall survival in the IMCgp100-202 study

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Perioperative durvalumab continues to show clinical benefit in patients with resectable stage IIA to IIIB NSCLC	0	9.27	17-09-2026
2	Perioperative durvalumab plus FLOT improves OS in patients with resectable gastric or GEJ adenocarcinoma	0	9.22	15-09-2026
3	Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma	0	5	09-07-2026
4	New treatment approach improves survival, reduces recurrence risk in muscle-invasive bladder cancer	0	11.13	24-07-2026
5	Comprehensive genomic profiling with subsequent molecularly guided therapy improves outcomes over platinum-based chemotherapy in previously untreated, unfavourable CUP	0	16.41	22-09-2026
6	FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC	5	7	24-06-2026
7	Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence	0	10	21-07-2026
8	Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer	0	11.1	13-07-2026
9	Malaga oncologists test ground-breaking drug that sheds light on pancreatic cancer	0	18.7	13-07-2026
10	Pembrolizumab Plus Chemotherapy for Cervical Cancer	0	14.76	10-09-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 14.93. Источник: www.esmo.org.